Skip to main content
Erschienen in: Abdominal Radiology 4/2013

01.08.2013

Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging

verfasst von: A. Gatto, A. M. De Gaetano, M. Giuga, M. Ciresa, L. Siciliani, L. Miele, L. Riccardi, F. Pizzolante, G. L. Rapaccini, A. Gasbarrini, F. Giuliante, F. M. Vecchio, M. Pompili, L. Bonomo

Erschienen in: Abdominal Radiology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We evaluated whether the addition of delayed phase imaging (DPI) gadobenate dimeglumine-enhanced MRI to dynamic postcontrast imaging improves the characterization of small hepatocellular carcinoma (HCC) and the differentiation between HCC, high grade dysplastic nodules (HGDN), and low grade dysplastic nodules (LGDN).

Methods

Twenty-five cirrhotic patients with 30 nodules (16 HCC, 8 HGDNs, and 6 LGDNs; maximum size of 3 cm) were included in this retrospective study. The diagnostic reference standard was histology. All the patients underwent MRI both prior to and following intravenous administration of gadobenate dimeglumine. The lesions were classified as hypointense, isointense, hyperintense on DPI for qualitative assessment. In the quantitative analysis the relative tumor-liver contrast to noise ratio (CNR) of the lesions on DPI was calculated.

Results

All HCCs were hypointense on DPI while only 8 (57.1%) of 14 DNs were hypointense and only 1 of 6 (16.6%) LGDNs was hypointense. There was a statistically significant difference in the hypointensity on DPI between HCCs and DNs (p = 0.003) in the qualitative analysis but not in the CNR values while there was a strong statistically significant difference in the hypointensity on DPI in the qualitative (p = 0.00001) and quantitative analysis (p < 0.05) between LGDNs and the group obtained by unifying HGDNs and HCCs.

Conclusion

DPI is helpful in differentiating HCCs and HGDNs from LGDNs. Demonstration of hypointensity on DPI should raise the suspicion of HGDN or hypovascular HCC in the case of nodules with atypical dynamic pattern.
Literatur
1.
Zurück zum Zitat Amit S, Jorge AM (2008) Screening for hepatocellular carcinoma. Gastroenterol Hepatol (NY) 4(3):201–208 Amit S, Jorge AM (2008) Screening for hepatocellular carcinoma. Gastroenterol Hepatol (NY) 4(3):201–208
2.
Zurück zum Zitat Hussain SM, Zondervan PE, IJzermans JN, et al. (2002) Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. Radiographics 22:1023–1036PubMed Hussain SM, Zondervan PE, IJzermans JN, et al. (2002) Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. Radiographics 22:1023–1036PubMed
3.
Zurück zum Zitat Matsui O, Kadoya M, Kameyama T, et al. (1991) Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 178:493–497PubMed Matsui O, Kadoya M, Kameyama T, et al. (1991) Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 178:493–497PubMed
4.
Zurück zum Zitat Bartolozzi C, Battaglia V, Bozzi E (2011) Hepatocellular nodules in liver cirrhosis: contrast-enhanced MR. Abdom Imaging 36:290–299PubMedCrossRef Bartolozzi C, Battaglia V, Bozzi E (2011) Hepatocellular nodules in liver cirrhosis: contrast-enhanced MR. Abdom Imaging 36:290–299PubMedCrossRef
5.
Zurück zum Zitat Caudana R, Morana G, Pirovano G, et al. (1996) Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)—preliminary results of phase II clinical application. Radiology 199:513–520PubMed Caudana R, Morana G, Pirovano G, et al. (1996) Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)—preliminary results of phase II clinical application. Radiology 199:513–520PubMed
6.
Zurück zum Zitat Kim YK, Lee JM, Kim CS (2004) Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 14:5–13PubMedCrossRef Kim YK, Lee JM, Kim CS (2004) Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 14:5–13PubMedCrossRef
7.
Zurück zum Zitat Pirovano G, Vanzulli A, Marti-Bonmati L, et al. (2000) Evaluation of the Accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. Am J Roentgenol 175:1111–1120CrossRef Pirovano G, Vanzulli A, Marti-Bonmati L, et al. (2000) Evaluation of the Accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. Am J Roentgenol 175:1111–1120CrossRef
8.
Zurück zum Zitat Manfredi R, Maresca G, Baron RL, et al. (1999) Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 9:704–710PubMedCrossRef Manfredi R, Maresca G, Baron RL, et al. (1999) Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 9:704–710PubMedCrossRef
9.
Zurück zum Zitat Bruix J, Sherman M (2011) American association for the study of liver diseases. Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022PubMedCrossRef Bruix J, Sherman M (2011) American association for the study of liver diseases. Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022PubMedCrossRef
10.
Zurück zum Zitat International Working Party (1995) Terminology of nodular hepatocellular lesions. Hepatology 22:983–993 International Working Party (1995) Terminology of nodular hepatocellular lesions. Hepatology 22:983–993
11.
Zurück zum Zitat International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49:658–664CrossRef International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49:658–664CrossRef
12.
13.
14.
Zurück zum Zitat Spinazzi A, Lorusso V, Pirovano G, Kirchin M (1999) Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 6:282–291PubMedCrossRef Spinazzi A, Lorusso V, Pirovano G, Kirchin M (1999) Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 6:282–291PubMedCrossRef
15.
Zurück zum Zitat Kirchin MA, Pirovano G, Spinazzi A (1998) gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 33:798–809PubMedCrossRef Kirchin MA, Pirovano G, Spinazzi A (1998) gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 33:798–809PubMedCrossRef
16.
Zurück zum Zitat Cavagna FM, Maggioni F, Castelli PM, et al. (1997) Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 32:780–796PubMedCrossRef Cavagna FM, Maggioni F, Castelli PM, et al. (1997) Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 32:780–796PubMedCrossRef
17.
Zurück zum Zitat Pena CS, Saini S, Baron RL, et al. (2001) Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial. Korean J Radiol 2(4):210–215PubMedCrossRef Pena CS, Saini S, Baron RL, et al. (2001) Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial. Korean J Radiol 2(4):210–215PubMedCrossRef
18.
Zurück zum Zitat Kim JI, Lee JM, Choi JY, et al. (2008) The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 43(3):202–210PubMedCrossRef Kim JI, Lee JM, Choi JY, et al. (2008) The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 43(3):202–210PubMedCrossRef
19.
Zurück zum Zitat Bartolozzi C, Battaglia V, Bozzi E (2009) HCC diagnosis with liver-specific MRI-close to histopathology. Dig Dis 27:125–130PubMedCrossRef Bartolozzi C, Battaglia V, Bozzi E (2009) HCC diagnosis with liver-specific MRI-close to histopathology. Dig Dis 27:125–130PubMedCrossRef
20.
Zurück zum Zitat Kim TK, Lee KH, Jang HJ, et al. (2011) Analysis of gadobenate dimeglumine-enhanced MR Findings for characterizing small (1–2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology 259(3):730–738PubMedCrossRef Kim TK, Lee KH, Jang HJ, et al. (2011) Analysis of gadobenate dimeglumine-enhanced MR Findings for characterizing small (1–2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology 259(3):730–738PubMedCrossRef
21.
Zurück zum Zitat Morana G, Grazioli L, Kirchin MA, et al. (2011) Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol 46(4):225–239PubMedCrossRef Morana G, Grazioli L, Kirchin MA, et al. (2011) Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol 46(4):225–239PubMedCrossRef
22.
Zurück zum Zitat Tahir B, Sandrasegaran K, Ramaswamy R, et al. (2011) Does the hepatocellular phase of gadobenate dimeglumine help to differentiate hepatocellular carcinoma in cirrhotic patients according to histological grade? Clin Radiol 66(9):845–852PubMedCrossRef Tahir B, Sandrasegaran K, Ramaswamy R, et al. (2011) Does the hepatocellular phase of gadobenate dimeglumine help to differentiate hepatocellular carcinoma in cirrhotic patients according to histological grade? Clin Radiol 66(9):845–852PubMedCrossRef
23.
Zurück zum Zitat Matsui O (2004) Imaging of multistep human hepatocarcinogenesis by CT during intra-arterial contrast injection. Intervirology 47(3–5):271–276PubMedCrossRef Matsui O (2004) Imaging of multistep human hepatocarcinogenesis by CT during intra-arterial contrast injection. Intervirology 47(3–5):271–276PubMedCrossRef
24.
Zurück zum Zitat Matsui O, Kobayashi S, Sanada J, et al. (2011) Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 36(3):264–272PubMedCrossRef Matsui O, Kobayashi S, Sanada J, et al. (2011) Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 36(3):264–272PubMedCrossRef
25.
Zurück zum Zitat Willatt JM, Hussain HK, Adusumilli S, Marrero JA (2008) MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 247(2):311–329PubMedCrossRef Willatt JM, Hussain HK, Adusumilli S, Marrero JA (2008) MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 247(2):311–329PubMedCrossRef
26.
Zurück zum Zitat Theise ND, Park YN, Kojiro M, et al. (2002) Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 6(2):497–512PubMedCrossRef Theise ND, Park YN, Kojiro M, et al. (2002) Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 6(2):497–512PubMedCrossRef
27.
Zurück zum Zitat Kobayashi M, Ikeda K, Hosaka T, et al. (2006) Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer 106(3):636–647PubMedCrossRef Kobayashi M, Ikeda K, Hosaka T, et al. (2006) Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer 106(3):636–647PubMedCrossRef
28.
Zurück zum Zitat Borzio M, Fargion S, Borzio F, et al. (2003) Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 39(2):208–214PubMedCrossRef Borzio M, Fargion S, Borzio F, et al. (2003) Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 39(2):208–214PubMedCrossRef
Metadaten
Titel
Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging
verfasst von
A. Gatto
A. M. De Gaetano
M. Giuga
M. Ciresa
L. Siciliani
L. Miele
L. Riccardi
F. Pizzolante
G. L. Rapaccini
A. Gasbarrini
F. Giuliante
F. M. Vecchio
M. Pompili
L. Bonomo
Publikationsdatum
01.08.2013
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 4/2013
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-012-9950-y

Weitere Artikel der Ausgabe 4/2013

Abdominal Radiology 4/2013 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

13.04.2024 Klinik aktuell Kongressbericht

Die Teilnehmer eines Forums beim DGIM-Kongress waren sich einig: Fehler in der Medizin sind häufig in ungeeigneten Prozessen und mangelnder Kommunikation begründet. Gespräche mit Patienten und im Team können helfen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.